BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24607027)

  • 1. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
    Kunadian V; Giugliano RP; Newby LK; Zorkun C; Guo J; Bagai A; Montalescot G; Braunwald E; Califf RM; Van de Werf F; Armstrong PW; Harrington R; Gibson CM
    Am J Cardiol; 2014 Apr; 113(8):1297-305. PubMed ID: 24607027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
    Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
    Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
    Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM;
    JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
    Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK
    Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
    Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
    N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial.
    Gibson CM; Kirtane AJ; Murphy SA; Rohrbeck S; Menon V; Lins J; Kazziha S; Rokos I; Shammas NW; Palabrica TM; Fish P; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):668-75. PubMed ID: 16996831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
    Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN
    J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions.
    Halim SA; Clare RM; Newby LK; Lokhnygina Y; Schweiger MJ; Hof AW; Hochman JS; James SK; White HD; Widimsky P; Betriu A; Bode C; Giugliano RP; Harrington RA; Zeymer U
    Int J Cardiol; 2016 Jan; 203():708-13. PubMed ID: 26587725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.
    Farhan S; Clare RM; Jarai R; Giugliano RP; Lokhnygina Y; Harrington RA; Kristin Newby L; Huber K
    Int J Cardiol; 2017 Apr; 232():264-270. PubMed ID: 28089149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.
    Gibson CM; Murphy SA; Marble SJ; Cohen DJ; Cohen EA; Lui HK; Young J; Kitt MM; Lorenz TJ; Tcheng JE
    Am Heart J; 2002 Jan; 143(1):106-10. PubMed ID: 11773919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
    Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy.
    Pride YB; Tung P; Mohanavelu S; Zorkun C; Wiviott SD; Antman EM; Giugliano R; Braunwald E; Gibson CM;
    JACC Cardiovasc Interv; 2010 Aug; 3(8):806-11. PubMed ID: 20723851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
    Le May MR; Wells GA; Glover CA; So DY; Froeschl M; Marquis JF; O'Brien ER; Turek M; Thomas A; Kass M; Jadhav S; Labinaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):330-8. PubMed ID: 20031736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction.
    Pinto DS; Kirtane AJ; Ruocco NA; Deibele AJ; Shui A; Buros J; Murphy SA; Gibson CM
    Am J Cardiol; 2005 Dec; 96(11):1494-7. PubMed ID: 16310428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.